Study identifier:D1320C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of AZD8566 in Healthy Volunteers
pharmacokinetics
Phase 1
Yes
AZD8566, Placebo
All
36
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD8566 10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee |
Placebo Comparator: 2 | Drug: Placebo 10ml oral solution administered once a day over 10 days. |